Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 5Phase 1/2 4

Status

Completed 3Active not recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 3Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1ALK+ Advanced NSCLC 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Has results × alectinib × Clear all
NCT02075840 2026-05-29

ALEX

Hoffmann-La Roche

Phase 3 Completed
303 enrolled 32 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Hoffmann-La Roche

Phase 3 Active not recruiting
257 enrolled 14 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Hoffmann-La Roche

Phase 3 Active not recruiting
187 enrolled 14 charts
Thoracic

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed
248 enrolled 20 charts
Thoracic

ALK+ Advanced NSCLC

NCT02604342 2019-10-29

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Hoffmann-La Roche

Phase 3 Completed
119 enrolled 33 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡